Stablecoin yield debate continues to stall CLARITY Act progress The search for the best cryptos to buy under $1 is happening against a backdrop of heated debateStablecoin yield debate continues to stall CLARITY Act progress The search for the best cryptos to buy under $1 is happening against a backdrop of heated debate

Best Cryptos to Buy Now Under $1 in March 2026: PUMP and CFG Show Recovery While Pepeto Carries the $7.391 Million Conviction Signal No Other Presale Has Matched

2026/03/07 04:30
5 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Stablecoin yield debate continues to stall CLARITY Act progress

The search for the best cryptos to buy under $1 is happening against a backdrop of heated debate over the CLARITY Act and stablecoin yields. At the centre of the argument is whether stablecoin issuers like Circle and Tether should be regulated as banks if they offer yield bearing products, as reported by CoinDesk. JPMorgan CEO Jamie Dimon has been the loudest banking voice arguing for bank equivalent regulation. President Trump struck back, accusing banks of undermining his GENIUS Act and calling for immediate resolution.

The debate has been running for months and the market is tired of waiting. Investors who expected clarity in Q1 are now pricing in a Q2 resolution at the earliest. That delay is pushing capital toward assets where the rules are already clear, which is exactly why presale projects with defined tokenomics and solid audits are attracting the most attention.

Best Cryptos to Buy Now Under $1 in March 2026: PUMP and CFG Show Recovery While Pepeto Carries the $7.391 Million Conviction Signal No Other Presale Has Matched

Whatever the outcome, stablecoins are becoming a core part of every serious crypto portfolio. But for growth, altcoins under $1 remain the engine. And in this market, the projects that combine real utility with early stage pricing are generating the most investor attention.

Best cryptos to buy now under $1 in March 2026

Pepeto (PEPETO)

The $7.391 million that Pepeto has raised during this fear cycle is a number that deserves attention. This is not retail FOMO money. This is investor grade conviction deployed during extreme market fear, when most people were selling, not buying.

Pepeto is in presale at $0.000000186. The PEPE founders are behind it. The team has announced PepetoSwap, a cross chain bridge, and a full trading exchange, all three confirmed and approaching launch. Dual audits from SolidProof and Coinsult returned zero vulnerabilities. Staking runs at 200% APY.

The post listing analyst target is $0.0001, which is 537 times the current price. A $11,000 entry becomes $5,907,000 at that target. That is the kind of number that changes a financial situation permanently. And it is sitting at $0.000000186 right now.

Pump.fun (PUMP)

Pump.fun is trading at $0.002011, up from $0.001719 on February 28. The 17% recovery in five days signals improving momentum. The platform recently updated its mobile app to support trading of tokens from rival Solana launchpads including Raydium and Meteora, along with established assets like Wrapped Bitcoin, expanding its utility beyond native bonding curve tokens. According to CoinMarketCap, PUMP remains below its December peak near $0.0030. That undervaluation, combined with the platform’s revenue sharing model for token holders, keeps PUMP on the shortlist for best cryptos to buy under $1.

Centrifuge (CFG)

Centrifuge is trading at $0.15, more than doubled from its February low of $0.067. CFG powers the tokenization infrastructure behind products like Janus Henderson’s tokenized CLOs and the Lista DAO RWA platform on BNB Chain. The total value locked in Centrifuge’s ecosystem surpassed $1 billion in 2025. The 2026 roadmap includes tokenized index fund expansion and new whitelabel partnerships. CFG sits significantly below its all time high of $0.40, making it one of the more undervalued tokens in the RWA sector.

Conclusion

The stablecoin debate will eventually be resolved. PUMP is recovering. CFG is building. But the standout on this list is not under $1. It is at $0.000000186. And the $7.391 million committed to Pepeto by investors who moved during maximum fear is proof that the smartest money in this market already knows it.

PEPE made 537x returns accessible for people who moved early. Pepeto has the same team, better infrastructure, and an open presale. A $11,000 entry targets $5,907,000. The best cryptos to buy under $1 are compelling. But the best crypto to buy right now is still in presale.

Click To Visit Pepeto Website To Enter The Presale

FAQs

What are the best cryptos to buy now under $1 in March 2026?

The best cryptos to buy under $1 in March 2026 include Pump.fun at $0.002011, Centrifuge at $0.15, and Pepeto at $0.000000186. Pepeto leads the list because it has raised $7.391 million, has three DeFi products announced by the PEPE founders, and targets a 537x return at listing.

What is behind Pepeto’s $7.391 million presale raise?

Pepeto raised $7.391 million because it is backed by the PEPE founders and enters the market with three announced DeFi products nearing launch. The combination of proven meme coin heritage, dual zero vulnerability audits, and 200% APY staking has attracted institutional level conviction during a market downturn.

Is Pump.fun (PUMP) a good investment right now?

PUMP is trading at $0.002011 and showing early recovery signs after expanding to support rival Solana launchpad tokens. The revenue sharing model for token holders adds utility. It sits below its recent peak of $0.0030, suggesting upside. However, Pepeto at $0.000000186 with a 537x target offers significantly better risk to reward.

Comments
Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.0004868
$0.0004868$0.0004868
-6.65%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09